Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
BPC-157: The Gut and Tissue Protector BPC-157 at 10 mg per vial serves double duty in the Retatrutide + GLOW stack
Based on Phase 2 trial data, the most common early side effects are nausea, vomiting, diarrhoea, constipation, and reduced appetite, consistent with the GLP-1 receptor agonist class
However, retatrutide has not yet received marketing authorisation from the MHRA or EMA, meaning it is not currently available as a licensed medicine in the UK
Lundgren Julie, R
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
